Bildkälla: Stockfoto

IRLAB: Positive outcome from end-of-phase 2 meeting - Redeye

Redeye gives a short comment on the exciting news that the FDA and IRLAB have an aligned view on a future phase III program for Mesdopetam.

Redeye gives a short comment on the exciting news that the FDA and IRLAB have an aligned view on a future phase III program for Mesdopetam.
Börsvärldens nyhetsbrev
ANNONSER